Scientists have developed a way to deliver a nerve-protecting substance past the brain’s natural defenses using fat-based ‘bubbles,’ a strategy…
Articles by Margarida Maia, PhD
Dosing has begun in a new arm of the HEALEY ALS platform trial, with Regimen I — the ninth —…
The experimental therapy QRL-201 successfully reached its biological target and showed early signs that it may slow disease progression in…
Early treatment with PrimeC, an experimental oral treatment being developed by Neurosense Therapeutics, significantly extended survival in people with…
In the U.S., clinical trials for amyotrophic lateral sclerosis (ALS) do not include enough non-white patients and women to…
Partially lowering levels of the protein RAD23A can help nerve cells better handle toxic TDP-43 protein clumps, improving survival and…
Tanabe Pharma plans to establish a new U.S.-based company to hold the global rights to Radicava and Radicava…
Both people living with amyotrophic lateral sclerosis (ALS) and their caregivers benefit most from flexible, personalized psychological support that…
QRL-101, an experimental oral small molecule being developed by Quralis for amyotrophic lateral sclerosis (ALS), was found in…
Throughout 2025, ALS News Today delivered readers timely reporting on research breakthroughs, patient advocacy, potential treatments, and diagnostic advances…